In vivo and in vitro anti-inflammatory and anti-nociceptive activities of lovastatin in rodents. D.O. Gonçalves, I.B.F. Calou, R.P. Siqueira, A.A. Lopes, L.K.A. Leal, G.A.C. Brito, A.R. Tomé and G.S.B. Viana. Braz J Med Biol Res 2011; 44: 173-181.

Figure 5. A, B, C, Hematoxylin and eosin (H/E) staining of rat paws in the model of carrageenan-induced edema. Micrographs (400X) of representative paw slices from each group are shown. A, Sham (untreated) control; B, inflammation control (with carrageenan treatment); C, inflammation lovastatin (LOV pretreatment, 5 mg/kg, po, followed by carrageenan administration 1 h later). Some of these changes are indicated by arrows as e (edema), i (inflammatory cell infiltration), and f (collagen fiber preservation). D, E, F, Immunohistochemistry for inducible nitric oxide synthase (iNOS) in the model of acute paw edema induced by carrageenan in rats. Micrographs (400X) of representative paw slices from each group are shown. D, Sham (untreated) control; E, inflammation control (treatment with carrageenan); F, inflammation lovastatin (LOV pretreatment, 5 mg/kg, po, followed by carrageenan administration 1 h later). The presence of immunostaining is indicated by an arrow as is. G, H, I, Immunohistochemistry for tumor necrosis factor-alpha (TNF-α) in the model of acute paw edema induced by carrageenan in rats. Micrographs (400X) of representative paw slices from each group are shown. G, Sham (untreated) control; H, inflammation control (treatment with carrageenan); I, inflammation lovastatin (LOV pretreatment, with 5 mg/kg, po, followed by carrageenan administration 1 h later). The presence of immunostaining is indicated by an arrow as is.